You did everything right.
You took the shot every week. You didn't skip. The weight came off — real weight, the kind people noticed — and then one month the scale just stopped. Same dose. Same habits. Same you. Different result.
If you're reading this on a Tuesday night wondering whether you wasted a year, we'd like to offer a different frame.
A plateau is not a failure. It's information. It's telling you something specific about what's happening in your body, and there are about four different things it can be saying. The trouble is that "it stopped working" describes a number on a scale, not a diagnosis — and you can't fix what you haven't identified. So, let's identify it.
Key Takeaways
- A plateau is expected, not exceptional. Weight loss on GLP-1 medications was never going to be a straight line, and most people level off somewhere between one and two years.
- Check the dose first. A lot of people stall on a maintenance dose they assumed was the maximum when it wasn't.
- Muscle loss is the quiet driver. Losing lean tissue lowers what you burn at rest, and it's partly preventable with protein and resistance training.
- Some people are low responders. That's biology, not effort, and it's the reason obesity medicine treats these drugs as one tool rather than the whole toolbox.
- Stopping because you plateaued is the wrong move. A plateau means you're holding a loss you'd otherwise regain.
- There's a structural option. For people who've plateaued and still carry significant weight, endoscopic sleeve gastroplasty changes the equation instead of adding to it.
First question: is this a plateau, or is this the finish line?
Here's something nobody tells you at the start.
Weight loss on these medications was never designed to continue forever. In the trials, the weight came off fastest in the early months, then flattened — and most people approached their plateau somewhere in the range of a year to eighteen months.
The semaglutide trial found an average total loss of around 15% of body weight over about 68 weeks. Tirzepatide did better, with the highest dose averaging closer to 21% over 72 weeks. Those are averages, and averages hide a lot — plenty of people lose more, and a real number of people lose considerably less.
So before you ask why did it stop, ask a better question: Where did it stop, and is that roughly where it was always going to stop?
If you've lost 14% of your body weight on semaglutide and levelled off, the medication didn't fail you. It did exactly what it does. Whether that's enough for you is a completely separate question — and a fair one. But it's a different conversation than "this isn't working."
Second question: are you actually on the dose you think you're on?
This one catches more people than you'd expect.
These medications are titrated up slowly over months. Somewhere in that process, a lot of people settle onto a dose, get comfortable, and assume they've reached the top of the range. Often they haven't.
If you plateaued while you were still climbing, your plateau might be a prescription question rather than a biological ceiling.
Three things worth asking whoever prescribes for you:
- What dose am I actually on right now?
- What's the maximum approved dose for this medication?
- Is there a clinical reason I shouldn't go higher?
You may get a good answer to the third one. Side effects, other conditions, and your own history all matter. But you should know the answer either way.\
Third question: what changed without you noticing?
Appetite suppression doesn't stop working, exactly. What happens is that you adapt around it.
Portions creep back. The glass of wine returns. The handful of something at 9pm becomes a habit again. None of this is a willpower problem — it's what a year does to anyone, and it's genuinely invisible unless someone's measuring.
But there are also things that have nothing to do with what you're eating, and these are worth raising with your physician:
Other medications. Several common ones work directly against weight loss — certain antidepressants, steroids, and some blood pressure and diabetes drugs among them. If you started something new in the last year, that timing matters.
Conditions that aren't fully controlled. An underactive thyroid or untreated sleep apnea makes weight loss materially harder. Both are common. Both are treatable. Neither is obvious without testing. If you've never been screened for sleep apnea and you snore, that's worth a conversation. Same for thyroid function if you're tired in a way that sleep doesn't fix.
Muscle. This is the one we'd underline.
Any significant weight loss takes lean tissue along with fat. Lost muscle lowers the energy you burn at rest — which means the same food that used to create a deficit no longer does. It's one of the most underappreciated causes of a stall, it hits harder after 50, and it's partly preventable with enough protein and some resistance training.
If nobody has talked to you about protein and lifting, that's a gap in your care, not a gap in your discipline.
Fourth question: are you a low responder?
Some people don't respond strongly to these medications. Not because they cheated, not because they didn't try, their biology just doesn't answer the way the average patient's does.
It's a known, documented pattern. It isn't rare. And it's precisely why obesity medicine treats GLP-1s as one tool rather than the answer.
If you've been fully adherent, you're at a full dose, everything else has been checked, and the result still isn't where you need it to be, the honest next conversation isn't about trying harder. It's about trying something different.
So what are the actual options?
Once you know which of the four you're dealing with, the path forward gets a lot clearer.
Option 1 — Optimize what you already have. Finish the titration. Fix the protein. Add resistance training. Review the medications working against you. Treat the thyroid or the sleep apnea. For a lot of people this is genuinely enough, and it should always be the first thing you exhaust.
Option 2 — Change the medication. Semaglutide and tirzepatide aren't interchangeable, and they didn't produce the same results in trials. Switching is a real option — but it's a clinical decision made with a physician, not a preference you shop for. The NIDDK maintains a plain-language overview of the approved options if you want to read up before your appointment.
Option 3 — Consider a structural change.
If you've plateaued and you're still carrying significant excess weight, this is the option most people don't know exists.
Endoscopic sleeve gastroplasty — ESG — reduces the size of your stomach using a suturing device passed through your mouth. No incisions. No staples. Nothing removed. You go home the same day.
What makes it different from another dose or another drug is that it changes the equation rather than adding to it. It isn't a replacement for medical management, and it isn't right for everyone — but for someone whose medication has done what it's going to do, it's a genuinely different lever.
Dr. Mark Amorosino is board certified in both gastroenterology and obesity medicine, and performs ESG himself. That combination is unusual, and it's the reason this whole conversation can happen in one place instead of across three referrals.
If you want to understand how ESG compares to traditional surgery, we've written that up separately: ESG vs. gastric sleeve. And if you're wondering whether you'd even qualify, start here.
Three things not to do
Don't stop the medication because it plateaued. This is the most common mistake, and it's the most expensive one. A plateau means you're holding a loss you would otherwise regain. Stopping is a decision to make deliberately, with a plan, alongside your physician — not out of frustration on a bad week.
Don't raise your own dose, and don't buy medication outside a supervised prescription to do it. The FDA has published specific warnings about unapproved and compounded semaglutide sourced outside legitimate channels. This is not a corner worth cutting.
Don't accept "just eat less" as a plan. If that were sufficient, you wouldn't have needed the medication in the first place. You deserve a better answer than the one that already didn't work.
Frequently asked questions
How long does a GLP-1 plateau usually last? It depends entirely on the cause. A dosing plateau can break within weeks of a titration adjustment. A plateau driven by muscle loss or an untreated thyroid takes as long as it takes to address the underlying issue. And if you've reached your medication's actual ceiling, it won't break at all without changing the approach — which is useful to know rather than discouraging.
Does everyone plateau on semaglutide or tirzepatide? Essentially, yes. The trials show weight loss flattening for most people somewhere around 12 to 18 months. Plateauing is the expected shape of the curve, not a sign something has gone wrong.
Can I switch from semaglutide to tirzepatide if I've stalled? Sometimes, and for some people it helps. They're different medications with different average results. But it's a clinical decision that depends on your history, side effects, and what your plateau is actually caused by — which is why it starts with an appointment rather than a request.
Is ESG only for people who haven't tried medication? No — and this is a common misunderstanding. A meaningful share of ESG patients come to it precisely because they've done medical weight loss properly and reached its limit. The two approaches aren't competitors.
Will I have to stop my GLP-1 if I have ESG? That's a case-by-case clinical decision, and one to work through with Dr. Amorosino rather than decide in advance.
The short version
A plateau tells you the current approach has reached its limit. It does not tell you that you have.
The useful next step is working out which limit you actually hit — and that takes a physician who treats obesity as the medical condition it is, rather than as a compliance problem to be lectured about.
If you're stalled and you'd like a real answer to why, book a consultation. We'll start by figuring out which of the four is yours.
